2024ÄêÌìÏ·ΰ©´ó»á£¨WCLC£©½«ÓÚÍâµØÊ±¼ä9ÔÂ7ÈÕÖÁ10ÈÕÔÚÃÀ¹úÊ¥µØÑǸçÕÙ¿ª¡£¡£¡£¡£¡£¡£¡£ÔÚ´ó»áÐû²¼µÄ¡°×îÐÂÍ»ÆÆÕªÒª(Late Breaking Abstract£¬£¬£¬£¬£¬£¬LBA)¡±Ãûµ¥ÖУ¬£¬£¬£¬£¬£¬º²ÉÖÆÒ©ÔÑÐÁ¢ÒìÒ©°¢ÃÀÌæÄá¼°±¸ÊܹØ×¢µÄ¹ÜÏß²úÆ·HS-20093ÒÀ¸½ÓÅÒìµÄÑо¿Ð§¹û˫˫ÈëÑ¡£¡£¡£¡£¡£¡£¡£»£»£»£»£»£»°¢ÃÀÌæÄáÉÐÓÐ12ƪÁ¢ÒìЧ¹ûÈëÑ¡±¾½ì´ó»á£¬£¬£¬£¬£¬£¬ÄÚÈݺ¸Çи¨Öú¡¢¸¨Öú¡¢ÍŽữÁÆ¡¢ÍŽá·ÅÁÆ¡¢ÄÔ×ªÒÆµÈÁìÓò¡£¡£¡£¡£¡£¡£¡£
Part 1£º×îÐÂÍ»ÆÆÕªÒª£¨LBA£©
¡¾1.1¡¿ Aumolertinib Maintenance after Chemoradiotherapy in stage ¢ó Non-Small-Cell Lung Cancer: Interim Results of the phase ¢ó study (POLESTAR)
°¢ÃÀÌæÄáÓÃÓÚ·Å»¯Áƺó¢óÆÚ·ÇСϸ°û·Î°©µÄά³ÖÖÎÁÆ£º¢óÆÚÑо¿£¨POLESTAR£©µÄÖÐÆÚЧ¹û
¡¾1.2¡¿ Efficacy and Safety of HS-20093 in Extensive Stage Small Cell Lung Cancer in A Multicenter, Phase ¢ñ Study (ARTEMIS-001)
Ò»Ïî¶àÖÐÐÄ¡¢¢ñÆÚÑо¿£¨ARTEMIS-O01£©ÖÐ HS-20093 ÖÎÁÆÆÕ±éÆÚСϸ°û·Î°©µÄÁÆÐ§ºÍÇå¾²ÐÔ
×÷ÕߣºÍõ½à£¨Öйúҽѧ¿ÆÑ§ÔºÖ×ÁöÒ½Ôº£©
Part 2£ºÃÔÄã¿ÚÍ·±¨¸æ
¡¾2.1¡¿ Aumolertinib as adjuvant therapy in resectable ¢ñ-¢ó EGFR-mutant NSCLC : also effective in patients with high-risk relapse factors
°¢ÃÀÌæÄá×÷Ϊ¿ÉÇгý¢ñ-¢óÆÚEGFRÍ»±äNSCLC µÄ¸¨ÖúÖÎÁÆ£º¶Ô¾ßÓи´·¢¸ßΣÒòËØ»¼ÕßÒ²ÓÐÓÃ
×÷ÕߣºÒ¦½¡£¡£¡£¡£¡£¡£¡£¨¼ªÁÖÊ¡ÈËÃñÒ½Ôº£©
Part 3£ºÑо¿Éè¼Æ
¡¾3.1¡¿ MRD guiding treatment after Aumolertinib induction therapy for EGFRm+ stage ¢ó NSCLC in the MDT diagnostic model (APPROACH)
MDTÕïÁÆÄ£Ê½ÏÂEGFRÍ»±äÑôÐÔ²»¿ÉÇгý¢óÆÚ·ÇСϸ°û·Î°©¾°¢ÃÀÌæÄáÓÕµ¼ÖÎÁƺóMRD¶¯Ì¬¼à²âÖ¸µ¼ÖÎÁƾöÒéµÄÓÐÓÃÐÔºÍÇå¾²ÐÔÑо¿£ºÒ»Ï·ÅÐÔ¡¢¶àÖÐÐÄ¡¢¢óÆÚÁÙ´²Ñо¿
×÷ÕߣºÖÜÇå¡¢ÎâÒ»Áú£¨¹ã¶«Ê¡ÈËÃñÒ½Ôº£©
¡¾Öйúר³¡ÌÖÂÛ±Ú±¨¡¿
¡¾3.2¡¿ Efficacy and safety of Aumolertinib with radiotherapy in the treatment of unresectable locally advanced EGFR-mutant NSCLC: a phase ¢ò study
°¢ÃÀÌæÄáÍŽá·ÅÁÆÖÎÁƲ»¿ÉÇоÖÍíÆÚµÄEGFRÍ»±äNSCLCµÄÁÆÐ§ºÍÇå¾²ÐÔ:Ò»Ïî¢òÆÚÑо¿
×÷ÕߣºÃÏÏ齿£¨É½¶«Ê¡Ö×ÁöÒ½Ôº£©
Part 4£ºÑо¿Êý¾Ý
¡¾4.1¡¿ Aumolertinib as neoadjuvant therapy for EGFRm+ NSCLC: a subcohort analysis of PURPOSE trial data updated
°¢ÃÀÌæÄáи¨ÖúÖÎÁÆEGFRÍ»±äNSCLC»¼ÕߣºPURPOSEÊÔÑéµÄÐÐÁÐÆÊÎö
×÷Õߣº·½ÎÄÌΣ¨ÉϺ£ÊÐÐØ¿ÆÒ½Ôº£©
¡¾4.2¡¿ Aumolertinib in treatment-na?ve EGFR-mutant NSCLC patients with brain metastases: efficacy and safety data from the ARTISTRY
°¢ÃÀÌæÄáÖÎÁƳõÕï·ÇСϸ°û·Î°©£¨NSCLC£©°éÄÔ×ªÒÆµÄÓÐÓÃÐÔÓëÇå¾²ÐÔ£ºARTISTRYÑо¿ÐÐÁÐ1
×÷ÕߣºÕÅÏþ¾ê¡¢Íõ»Û¾ê£¨ºÓÄÏÊ¡Ö×ÁöÒ½Ôº£©
¡¾4.3¡¿ Aumolertinib with chemotherapy as first-line treatment in patients with EGFR-mutated advanced NSCLC: a real-world study
°¢ÃÀÌæÄáÍŽữÁÆÒ»ÏßÖÎÁÆEGFRÍ»±äÍíÆÚNSCLC»¼ÕߣºÒ»ÏîÕæÊµÌìÏÂÑо¿
×÷ÕߣºÐíÓÈÎï¡¢¹ùÈË»¨£¨½ËÕÊ¡ÈËÃñÒ½Ôº£©
¡¾4.4¡¿ Aumolertinib as adjuvant therapy in postoperative EGFR-mutated stage ¢ñ NSCLC with multiple high-risk factors
°¢ÃÀÌæÄḨÖúÖÎÁÆEGFRÍ»±ä°é¶àÖØ¸ßΣÒòËØµÄ¢ñÆÚNSCLC
×÷ÕߣºÎâÆë·É£¨Î÷°²½»´óÒ»¸½Ôº£©
¡¾4.5¡¿ Safety and efficacy of cranial radiotherapy in combination with Aumolertinib in EGFR-mutant NSCLC patients with brain metastases
EGFRÍ»±ä·ÇСϸ°û·Î°©ÄÔ×ªÒÆ°¢ÃÀÌæÄáÍŽᾫ׼·ÅÁƵÄÁÆÐ§ºÍÇå¾²ÐÔ
×÷Õߣº±Ï骣¨Öйúҽѧ¿ÆÑ§ÔºÖ×ÁöÒ½Ôº£©
¡¾4.6¡¿ Adjuvant Aumolertinib in resected stage I EGFR-mutated NSCLC: prospectively evaluating efficacy in residual GGN lesions
°¢ÃÀÌæÄáÖÎÁÆEGFRÍ»±äIÆÚ·Î°©ÇгýÊõºó²ÐÁô·ÎÄ¥²£Á§½á½Ú
×÷Õߣº»Æ³ç±ê£¨Ìì½òÒ½¿Æ´óѧÖ×ÁöÒ½Ôº£©
¡¾4.7¡¿ Adjuvant Aumolertinib in patients with completely resected, stage ¢ñA2-¢óA Non-Small-Cell Lung Cancer with uncommon EGFR mutations
°¢ÃÀÌæÄḨÖúÖÎÁÆ¢ñA2-¢óAÆÚÓÐÊýEGFRÍ»±äNSCLC»¼Õß
×÷Õߣººú¼á£¨Õã½´óѧҽѧԺÁ¥ÊôµÚÒ»Ò½Ôº£©
¡¾4.8¡¿ Efficacy and safety of Aumolertinib in stage ¢ñB-¢óA NSCLC after R0 resection and the correlation between efficacy and postoperative MRD status
°¢ÃÀÌæÄáÊõºó¸¨ÖúÖÎÁÆR0ÇгýµÄ¢ñB-¢óAÆÚNSCLC»¼ÕßµÄÁÆÐ§ºÍÇå¾²ÐÔÒÔ¼°ÊõºóMRDÓëÁÆÐ§Ïà¹ØÐÔµÄÑо¿
×÷ÕߣºÑîʤÀû£¨·ðɽÊеÚÒ»ÈËÃñÒ½Ôº£©
Part 5£º²¡ÀýϵÁÐ
¡¾5.1¡¿ High-dose Aumolertinib combined intrathecal chemotherapy for the treatment of EGFR-mutated NSCLC with leptomeningeal metastasis
¸ß¼ÁÁ¿°¢ÃÀÌæÄáÍŽáÇÊÄÚ»¯ÁÆÖÎÁÆEGFRÍ»±äNSCLC°éÄÔÄ¤×ªÒÆ
×÷ÕߣºÍõΰ£¨ÖØÇì´óѧÁ¥ÊôÈýϿҽԺ£©
º²ÉÖÆÒ©ÊÇÖйúÁìÏȵÄÁ¢ÒìÇý¶¯ÐÍÖÆÒ©ÆóÒµ£¬£¬£¬£¬£¬£¬ÏÂÊôºÀÉÒ©Òµ¡¢³£Öݺã°îÒ©Òµ¡¢º²ÉÉúÎïÒ½Ò©µÈ×Ó¹«Ë¾£¬£¬£¬£¬£¬£¬ÖØµã¹Ø×¢¿¹Ö×Áö¡¢¿¹Ñ¬È¾¡¢ÖÐÊàÉñ¾ÏµÍ³¡¢´úл¼°×ÔÉíÃâÒßµÈÖØ´ó¼²²¡ÖÎÁÆÁìÓò£¬£¬£¬£¬£¬£¬ÖÂÁ¦ÓÚͨ¹ýÒ»Á¬Á¢ÒìÌá¸ßÈËÀàÉúÃüÖÊÁ¿¡£¡£¡£¡£¡£¡£¡£×èÖ¹ÏÖÔÚ£¬£¬£¬£¬£¬£¬¹«Ë¾ÒÑÉÏÊÐ7¿îÁ¢ÒìÒ©£¬£¬£¬£¬£¬£¬Á¢ÒìÒ©ÓªÊÕÕ¼±ÈÒÑÍ»ÆÆÖÁ67.9%¡£¡£¡£¡£¡£¡£¡£¹«Ë¾Ò»Á¬¶àÄêλ¾ÓÈ«ÇòÖÆÒ©ÆóÒµ°ÙÇ¿¡¢ÖйúÒ½Ò©Ñз¢²úÆ·Ïß×î¼Ñ¹¤ÒµÆóҵǰ3Ç¿£¬£¬£¬£¬£¬£¬Êǹú¼ÒÖØµã¸ßÐÂÊÖÒÕÆóÒµ¡¢¹ú¼ÒÊÖÒÕÁ¢ÒìÊ÷Ä£ÆóÒµ¡£¡£¡£¡£¡£¡£¡£¹«Ë¾ÓÚ2019Äê6ÔÂÔÚÏã¸ÛÁª½»Ëù¹ÒÅÆÉÏÊУ¨¹ÉƱ´úÂ룺03692.HK£©¡£¡£¡£¡£¡£¡£¡£¸ü¶àÐÅÏ¢Çë»á¼û£º/¡£¡£¡£¡£¡£¡£¡£
ǰհÐÔ˵Ã÷
±¾ÎÄÖ¼ÔÚÌṩÓйء°º²ÉÖÆÒ©¼¯ÍÅÓÐÏÞ¹«Ë¾¡±»òÆä×Ó¹«Ë¾µÈ¹ØÁª·½£¨Í³³Æ¡°¹«Ë¾¡±£©µÄÏà¹ØÐÅÏ¢£¬£¬£¬£¬£¬£¬²»×é³É¹«Ë¾ÐÅÏ¢Åû¶»òͶ×ÊÍÆ¼ö¡£¡£¡£¡£¡£¡£¡£
±¾ÎÄËùÐû²¼µÄÐÅÏ¢ÖпÉÄÜ»á°üÀ¨Ä³Ð©Ç°Õ°ÐÔ±íÊö£¬£¬£¬£¬£¬£¬ÀýÈçÉæ¼°ÓªÒµºÍ²úÆ·Ô¶¾°£¬£¬£¬£¬£¬£¬»ò¹«Ë¾ÍýÏë¡¢ÈÏÖª¡¢Ô¤ÆÚ¼°Õ½ÂÔ¡£¡£¡£¡£¡£¡£¡£ÕâЩ±íÊöÊǽ¨ÉèÔÚÍÆ²âÐÔ¼ÙÉèµÄÊý¾Ý»ù´¡ÉϵÄÕ¹Íû£¬£¬£¬£¬£¬£¬²¢·ÇÊǶÔδÀ´Éú³¤µÄ°ü¹Ü£¬£¬£¬£¬£¬£¬ÒòÆäÐÔ×ÓʹȻ¾ùÊÜÏà¹ØÎ£º¦ºÍ²»È·¶¨ÒòËØÓ°Ï죬£¬£¬£¬£¬£¬ÆäÖв¿·Ö»¹²»Êܹ«Ë¾¿ØÖÆÇÒÄÑÒÔÔ¤ÁÏ£¬£¬£¬£¬£¬£¬Í¶×ÊÕß¾ÙÐÐͶ×ʾöÒéʱӦÉóÉ÷ʹÓᣡ£¡£¡£¡£¡£¡£ÔÚʹÓá°ÖÂÁ¦ÓÚ¡±¡°Ô¤ÆÚ¡±¡°ÐÅÍС±¡°Õ¹Íû¡±¡°ÆÚÍû¡±¼°ÆäËûÀàËÆ´ÊÓï¾ÙÐбíÊöʱ£¬£¬£¬£¬£¬£¬·²Ó빫˾ÓйصÄÐÅÏ¢±íÊö£¬£¬£¬£¬£¬£¬¾ùÊôÓÚǰհÐÔ±íÊö¡£¡£¡£¡£¡£¡£¡£¹«Ë¾²¢ÎÞÒåÎñ¸üлòÐÞ¸ÄÕâЩǰհÐÔ±íÊö£¬£¬£¬£¬£¬£¬¹«Ë¾¡¢¹«Ë¾¶Ê¡¢¹ÍÔ±¡¢ÊðÀí¸Å²»¼ç¸ºÒòÈκÎǰհÐÔ±íÊö²»¿ÉʵÏÖ»òÄð³É²»×¼È·¶øÒýÖµÄÈκÎÔðÈΡ£¡£¡£¡£¡£¡£¡£
±¾ÐÂΟåÖеÄËùÓÐÐÅÏ¢½ö¼°ÓÚÐÂΟåÐû²¼Ö®ÈÕ£¬£¬£¬£¬£¬£¬ÎÞÂÛÊÇ·ñ·ºÆðÐÂ×ÊÁÏ¡¢Î´À´ÊÂÎñ»òÆäËûÇéÐΣ¬£¬£¬£¬£¬£¬³ý·ÇÖ´·¨ÒªÇ󣬣¬£¬£¬£¬£¬¹«Ë¾²¢ÎÞÔðÈλòÒåÎñ¸üлòÐ޸ĸõÈÐÅÏ¢¡£¡£¡£¡£¡£¡£¡£Í¶×ÊÕßÒ˲ÎÕÕº²ÉÖÆÒ©£¨03692.HK£©Í¨¸æ¼°²Æ±¨£¬£¬£¬£¬£¬£¬ÒÔ»ñÈ¡½öÓëÉÏÊй«Ë¾ÓйصÄÐÅÏ¢¡£¡£¡£¡£¡£¡£¡£